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Background
Optimal lymphocyte parameters and thresholds for the diagnosis of chronic lymphocytic
leukemia have been proposed by The National Cancer Institute sponsored Working Group and
recently updated by the International Workshop on chronic lymphocytic leukemia. However,
it is not clear how these criteria apply to patient management in daily clinical practice and
whether the lymphocyte thresholds recommended truly predict clinical outcome in early
chronic lymphocytic leukemia.
Design and Methods
For the purpose of this study, an observational database of the GIMEMA (Gruppo Italiano
Malattie Ematologiche dell’Adulto) which included 1,158 patients with newly diagnosed Binet
stage A chronic lymphocytic leukemia who were observed at different primary hematology
centers during the period 1991-2000, was used.
Results
Among 818 consecutive chronic lymphocytic leukemia patients with Rai stage 0 (i.e. no palpa-
ble lymphadenopathy or hepatosplenomegaly) who had flow cytometry evaluations at the
time of diagnosis and were included in a GIMEMA database, both absolute lymphocyte count
and B-cell count were of a similar value in predicting time to first treatment as continuous vari-
ables (P<0.0001). Receiver operating characteristic analysis identified an absolute lymphocyte
count of 11.5¥109/L and an absolute B-cell count of 10.0¥109/L as the best thresholds capable of
identifying patients who will require treatment from those with stable disease. However, in a
Cox’s multivariate analysis only the B-cell count retained its discriminating power (P<0.0001)
and the estimated rate of progression to chronic lymphocytic leukemia requiring treatment
among subjects with a B-cell count less than 10.0¥109/L was approximately 2.3% per year
(95% CI 2.1-2.5%) while it was 2-fold higher for patients with a B-cell count of 10.0¥109/L or
over (i.e. 5.2% per year; 95% CI 4.9-5.5%). Finally, in this community-based patient cohort,
the B-cell threshold defined by investigators at the Mayo Clinic (i.e. 11.0¥109/L) allowed
patients to be divided into two subsets with a higher and lower likelihood of treatment
(P<0.0001).
Conclusions
Our results, based on a retrospective patients’ cohort, provide a clear justification to retain the
B-cell count as the reference gold standard of chronic lymphocytic leukemia diagnosis and
imply that a count of 10¥109/L B cells is the best lymphocyte threshold to predict time to first
treatment. The use of clinical outcome to distinguish chronic lymphocytic leukemia from other
premalignant conditions, such as monoclonal B-cell lymphocytosis, is a pragmatic approach
meeting the patients’ need to minimize the psychological discomfort of receiving a diagnosis
of leukemia when the risk of adverse clinical consequences is low.
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Introduction 
The incidence and presenting features of chronic lym-
phocytic leukemia (CLL) have changed significantly in the
last thirty years1-3 Both the introduction of automated
blood counters in routine clinical practice and the evolu-
tion of flow cytometry have led to a lowering of the
absolute lymphocyte count (ALC) required for a diagnosis
of chronic lymphocytic leukemia (i.e. ≥5.0¥109/L).4 In
addition, the sensitivity of these diagnostic procedures has
allowed the identification of a new clinical entity defined
as monoclonal B-cell lymphocytosis (MBL), whose natural
history still has to be conclusively defined.5,6
From a clinical standpoint, the development of formal
criteria for the diagnosis of monoclonal B-cell lymphocy-
tosis proposed in 2005 guided the 2008 revisions of mini-
mal requirements for chronic lymphocytic leukemia diag-
nosis.7 Briefly, the new criteria recommend using the B-cell
count rather than the absolute lymphocyte count as a
basis for the diagnosis of chronic lymphocytic leukemia,
and suggest a B-cell threshold of 5.0¥109/L to distinguish
chronic lymphocytic leukemia from monoclonal B-cell
lymphocytosis.7
However, the selection of the B-cell threshold for the
diagnosis of chronic lymphocytic leukemia was arbitrary
and was not based on objective data of clinical outcome.
Given the seriousness of a diagnosis of leukemia and the
evolution of the diagnostic criteria of chronic lymphocytic
leukemia, information on how the quantitative evaluation
of the B-cell clone relates to the clinical outcome of the dis-
ease appears mandatory. Recently, the Mayo Clinic Group
looked at the correlation between diagnostic lymphocyte
parameters and the clinical outcome in a cohort of Rai
stage 0 patients who had molecular markers available and
whose follow-up information allowed an association with
either time to first treatment or overall survival.8,9
In order to contribute to this debate, and possibly to
confirm these observations, the GIMEMA (Gruppo
Italiano Malattie EMatologiche dell’Adulto) has used an
observational database that includes newly diagnosed
chronic lymphocytic leukemia patients in Binet stage A
and managed over a 10-year period outside the setting of
clinical trials according to a “wait and watch” policy. In
this large community-based cohort of patients, not influ-
enced by any referral bias, we focused on Rai stage 0
patients and analyzed the relationship between lympho-
cyte count and clinical outcome. This analysis addresses
critical issues, such as the choice of the lymphocyte
parameter (i.e. absolute lymphocyte count or B-cell count)
to be used for a correct diagnosis of chronic lymphocytic
leukemia and the identification of the lymphocyte thresh-
old that better predicts the risk of transformation into an
active disease requiring therapy.
Design and Methods
Patients
The GIMEMA CLL database includes previously untreated
chronic lymphocytic leukemia patients in Binet stage A who
were observed at different GIMEMA primary hematological cen-
ters during the period 1991-2000. All patients were managed out-
side therapeutic protocols according to a ‘‘wait and watch’’ poli-
cy. Overall, 1,158 patients from 25 centers were merged into a
preliminary working file. Information regarding age, gender, Rai
stage, absolute peripheral blood lymphocytosis and number of
lymph node sites involved were available for all 1,158 patients.
We excluded 20 patients (1.7%) because of inadequate follow up.
We used this database to identify 858 Rai stage 0 patients. All
patients had an absolute lymphocyte count of at least 5.0¥109/L
at the time of diagnosis, thus fulfilling both 1988 and 1996
National Cancer Institute-sponsored Working Group (NCI-WC)
guideline criteria for chronic lymphocytic leukemia.4,10 An
immunologically confirmed diagnosis by flow cytometry
(CD5+/SmIg weak and/or CD5/CD19 co-expression) was avail-
able in 818 patients (96.1%). The proportion of B cells and T cells
was determined in each patient and the absolute B-lymphocyte
count was calculated multiplying the percentage of CD19-posi-
tive cells by baseline absolute lymphocyte count. In the majority
of patients with B-cell lymphocytosis less than 5.0¥109/L (i.e. 102
of 124, 82.2%), in addition to CD19 positive cells, we assessed
the number of clonal B cells by CD5/CD19 co-expression.
Data management and analyses were performed in accordance
with the ethical guidelines of the GIMEMA Review Board and
the tenets of the Declaration of Helsinki. The study was also
evaluated and approved by the ethical committee of the Azienda
Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
Indication for therapy
Patients underwent sequential monitoring and the frequency
of follow-up visits was individualized according to patient risk;
this ranged from between three and 12 months (median 6
months). All physicians who registered patients into this obser-
vational GIMEMA database stated that they had used the NCI-
WG guidelines as a reference criteria for starting therapy.4,10 In
detail, the absolute lymphocyte count was not used as the sole
indicator for treatment. Active disease, requiring therapy, was
defined on the basis of at least one of the criteria set out in the
National Cancer Institute-sponsored Working Group guidelines.4
Statistical analysis
Time to first treatment was defined as the time between the
date of diagnosis and the date of initiation of first treatment or
the date of the last follow up at which the patient was known to
be untreated. Estimates of time to first treatment were calculated
using the Kaplan-Meier method. Likelihood ratio tests were used
to test effects of individual factors, either in univariate analysis or
jointly. Hazard ratios (HR) and confidence intervals (CI) for haz-
ard ratios were calculated from the Cox’s models. Optimal
thresholds for absolute lymphocyte counts and B-cell counts
relating to time to first treatment were determined using the
receiver operating characteristic (ROC) analysis. The area under
the ROC curve (AUC) can range from 0.5 (which indicates a test
with no information) to 1.0 (which indicates a perfect test).
Because hazard ratio calculates the magnitude of risk rather than
the model’s capacity to accurately classify patient outcome,
Harrell’s C-statistics were used to further evaluate the discrimi-
natory power of lymphocyte variables in terms of time to first
treatment.11
Results
Among 818 consecutive chronic lymphocytic leukemia
patients with Rai stage 0 who had flow cytometry evalu-
ation at the time of diagnosis and who were included in
the GIMEMA database, none had palpable lym-
phadenopathy or hepatosplenomegaly. Patients under-
went sequential monitoring and median follow up for
vital status and treatment status were 47 months and 32
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months (range 2-120 months), respectively. As of last fol-
low up, 48 (5.8%) patients had died and 143 (17.4%) had
experienced a disease progression that required treatment.
The number of deaths recorded in the GIMEMA database
was considered insufficient to perform an analysis of asso-
ciation between lymphocyte parameters and overall sur-
vival.
All patients included in the GIMEMA database had at
the time of first diagnosis an absolute lymphocyte count
of at least 5.0¥109/L (median 11.2¥109/L; range 5.0-220.0)
and met the diagnostic criteria of chronic lymphocytic
leukemia as established by both 1988 and 1996 NCI-WC
guidelines.4,10 In this patient cohort, B-cell counts ranged
from 1.0 to 209.0¥109/L (median 9.0¥109/L). At the time of
the present investigation, 124 patients (15.1%) would be
reclassified as monoclonal B-cell lymphocytosis using the
2008 chronic lymphocytic leukemia diagnostic criteria7
and the median B-cell count of this patient subgroup was
3.9¥109/L (range 1.0-4.9¥109/L); therefore, slightly higher
than the median B-cell count reported in two large mono-
clonal B-cell lymphocytosis series (2.7¥109/L and
3.3¥109/L, respectively).6,9 While absolute lymphocyte
count and B-cell count were strongly correlated for the
overall cohort of patients (r=0.938; P<0.0001) (Figure 1A),
no correlation between absolute lymphocyte count and B-
cell count was observed when the analysis was restricted
to subjects with a B-cell count less than 5.0¥109/L (r=-0.02;
P=0.789) (Figure 1B).
A comparison of the demographic and clinico-hemato-
logical characteristics at the time of first diagnosis
between patients reclassified as monoclonal B-cell lym-
phocytosis and those with Rai stage 0 failed to show any
difference between the two groups (Table 1). Also the like-
lihood of treatment for monoclonal B-cell lymphocytosis
patients was substantially similar to that of patients with
chronic lymphocytic leukemia Rai stage 0 (HR 1.55; 95%
CI 0.91-2.65; P=not significant) (Figure 2). Since patient
stratification into the two sub-groups (i.e. MBL and CLL,
respectively) reflected the absolute number of CD19 posi-
tive cells, we wondered whether results would have been
biased by an excess of polyclonal B-cells among subjects
with monoclonal B-cell lymphocytosis. A sub-analysis car-
ried out to assess the relationship between absolute B-cell
count and monoclonal B cells (i.e. CD5/CD19 positive)
revealed that 85 of 102 patients with monoclonal B-cell
lymphocytosis had rare polyclonal B cells (i.e. < 0.1¥109/L)
while in the remaining 17 cases the absolute number of
polyclonal B cells did not exceed 0.5¥109/L. These obser-
vations, similar to those reported by Shanafelt et al.,8 seem
to confirm that absolute CD19 positive B cells may be
considered a reliable surrogate of clonality in this subset of
patients.
Since the B-cell threshold proposed in the 2008 CLL
diagnostic criteria7 to differentiate monoclonal B-cell lym-
phocytosis from chronic lymphocytic leukemia (i.e.
5¥109/L) did not stratify patients with a different clinical
outcome with respect to the rate of progression requiring
therapy, we assessed the impact of the absolute lympho-
cyte count and B-cell count on time to first treatment ana-
lyzing these parameters as continuous variables (i.e. meas-
uring the risk of each 1.0¥109/L increase in the cell count).
Interestingly, both the absolute lymphocyte count and the
B-cell count were associated to time to first treatment (HR
ALC 1.018, 95% CI 1.012-1.024, P<0.0001; HR B-cell
count 1.019, 95% CI 1.013-1.025, P<0.0001).
In order to investigate which lymphocyte parameter (i.e.
absolute lymphocyte count or B-cell count) provided a
more accurate prediction of time to first treatment, a C-
statistic analysis, considered a measure of concordance
between observed and predicted time-dependent events,
was carried out. The results of this statistical evaluation
B-cell count: differentiating chronic lymphocytic leukemia from monoclonal
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Figure 1. (A) Relationship between ALC and B-cell count in 818
patients who met the  1988 and 1996 IWCLL-NCI diagnostic CLL cri-
teria (4) (i.e. ALC of at least 5.0¥109/L and immunologically con-
firmed diagnosis of CLL by flow cytometry). (B) Relationship between
ALC and B-cell count in 124 patients  who  would be reclassified as
MBL using the 2008 CLL diagnostic criteria.7
Table 1. Comparison of demographic and clinico-hematological fea-
tures between patients reclassified as MBL according to the 2008 CLL
diagnostic criteria and patients in Rai stage 0.
Variable                               B-cell count            B-cell count             P
                                             < 5x109/L                ≥5x109/L            value
                                               (n=124)                  (n=694)
Age (years)                               65 (32-100)                 66 (35-89)               0.88
Gender (M/F ratio)                        0.93                               1.05                     0.15
ALC  (109/L)                              6.0 (5.0-30.4)              12.3 (5.2-220)           0.0001
B-cell count (109/L)                 3.9 (1.0-4.9)               10.1 (5.0-209)           0.0001
Hemoglobin (g/dL)            13.9  (11.0-17.8)        14.0 (11.0-18.0)          0.29
Platelets  (109/L)                   184 (123-380)           176 (125-397)            0.90
b2-microglobulin (mg/L)    1.7 (0.5-2.43)             1.9 (0.2-2.56)            0.86
LDT         
≥12 mo.                                 64 (79.0%)                287 (81.1%)             0.67
<12 mo.                                 17 (21.0%)                67 (18.9%)
Patients requiring                       15.3%                         17.8%                   0.49
chemotherapy (%)
ALC: absolute lymphocyte count;  LDT: Lymphocyte Doubling Time. Continuous variables
(i.e. age,  ALC,  B-cell count,  hemoglobin,  platelets,  B2-microglobulin) were expressed as
median and compared using the Mann-Whitney test.  
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clearly demonstrated that both the absolute lymphocyte
count (c=0.50, P<0.001) and the B-cell lymphocytosis
(c=0.51, P<0.001) correctly predicted time to first treat-
ment.
We then considered what threshold at diagnosis best
identified patients requiring treatment from those with
stable disease. ROC analysis revealed that an absolute
lymphocyte count of 11.5¥109/L (area under the curve
(AUC) 0.664, sensitivity 69.72%, specificity 56.67%;
P=0.0001) (Figure 3A) and an absolute B-cell lymphocyte
count of 10.0¥109/L (AUC 0.651, sensitivity 64.71%,
specificity 61.21%; P=0.0001) (Figure 3B) best identified
those patients who needed treatment. Interestingly,
absolute B-cell count of 10.0¥109/L allowed an accurate
prediction of time to first treatment (c=0.62; P<0.0001). As
expected, the same does not apply for absolute B-cell
count of 5.0¥109/L (c=0.52; P=0.36).
A comparison of the demographic and clinico-hemato-
logical characteristics of the patients obtained at the time
of first diagnosis and carried out according to these cut-off
values demonstrated that age, gender distribution, platelet
count, beta2-microglobulin level and lymphocyte dou-
bling time (LDT) were similar among patients with low
and higher B-cell counts or absolute lymphocyte counts
(Tables 2 and 3). The only difference between groups
relied on a significantly lower hemoglobin level that char-
acterized patients with an absolute lymphocyte count
S. Molica et al.
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Table 2. Comparison  of demographic and clinico-hematological fea-
tures of Rai stage 0 patients stratified according to the absolute lym-
phocyte count (ALC) threshold (i.e. 11.5x109/L)  selected on the basis
of  clinical outcome (i.e. time to first treatment).
Variable                                       ALC                        ALC                  P
                                             <11.5x109/L          ≥11.5x109/L        value
                                                 (n=434)                  (n=384)                
Age (years)                                   65 (32-89)                 65 (32-100)            0.99
Gender (M/F ratio)                           0.96                              1.06                   0.82
Hemoglobin (g/dL)                14.0  (11.0-17.8)        13.8 (11.0-18.0)         0.04
Platelets (109/L)                        187 (125-379)            178 (124-369)          0.89
b2-microglobulin (mg/L)        1.8 (0.5-2.56)             1.9 (0.5-2.56)           0.55
LDT
≥12 mo.                                    190 (78.5%)               171 (83.4%)            0.40
<12 mo.                                       52 (21.5%                  34 (16.6%)
Patients requiring                            9.9%                           26.0%                0.0001
chemotherapy (%)
ALC: absolute lymphocyte count; LDT: lymphocyte doubling time. Continuous variables
(i.e.,  age,  hemoglobin,  platelets,  B2-microglobulin) were expressed as median and
compared using the Mann-Whitney test.   
Table 3. Comparison of demographic and clinico-hematological fea-
tures of Rai stage 0 patients stratified according to the absolute B-cell
count threshold (i.e. 10x109/L) selected on the basis of clinical out-
come (i.e. time to first treatment).
Variable B-cell count B-cell count P
< 10x109/L ≥ 10x109/L value
(n=465) (n=353)
Age (years) 66 (32-100) 65 (32-89) 0.42
Gender (M/F ratio) 0.99 1.02 0.82
Hemoglobin (g/dL) 14.0 (11.0-17.8) 13.8 (11.0-18.0) 0.01
Platelets (109/L) 168 (123-303) 176 (119-397) 0.92
b2-microglobulin (mg/L) 1.8 (0.5-2.56) 2.0 (0.2-2.56) 0.99
LDT 
≥ 12 mo. 208 (79.4%) 143 (82.7%) 0.40
< 12 mo. 54 (20.6%  30 (17.3%)
Patients requiring 10.3% 26.9% 0.0001
chemotherapy (%)
LDT: lymphocyte doubling time. Continuous variables (i.e. age,  hemoglobin, platelets,
B2-microglobulin) were expressed as median and compared using the Mann-Whitney
test.
Figure 2. Time to first treatment (TFT) for patients reclassified, at the
time of this analysis, as MBL using the 2008 CLL diagnostic criteria7
(i.e. absolute B-cell count <5.0x109/L) and CLL Rai stage 0 (i.e.
absolute B-cell count ≥5.0x109/L).
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Figure 3. Receiving operating characteristic (ROC) analysis of the
accuracy for ALC (A) and B-cell count (B). The accuracy is measured
by the area under the ROC curve.
greater than 11.5¥109/L (P=0.04) or a B-cell count greater
than 10¥109/L (P=0.01).
A graphic representation of how these thresholds work
in predicting time to first treatment is presented in Figures
4 and 5, respectively. It would appear that both the
absolute lymphocyte count and the B-cell count could be
considered interchangeable lymphocyte variables to pre-
dict patient clinical outcome. In fact, the likelihood of
treatment for patients with an absolute lymphocyte count
of 11.5¥109/L or greater (HR 2.78; 95% CI 1.94-3.99;
P<0.0001) or a B-cell lymphocyte count of 10.0¥109/L or
greater (HR 2.68; 95% CI 1.88-3.81; P<0.0001) was sub-
stantially higher than that of patients with lower counts.
However, in a Cox’s multivariate analysis only the B-cell
count retained its discriminating power (P<0.0001) and
during the first five years of follow up the estimated rate
of progression to an active phase of the disease requiring
treatment was approximately 2.3% per year (95% CI 2.1-
2.5%) among subjects with a B-cell count less than
10.0¥109/L. Interestingly, such an estimate was 2-fold
higher for patients with a B-cell count of 10.0¥109/L or
greater (i.e. 5.2% per year; 95% CI 4.9-5.5%).
Finally, we wondered whether the B-cell threshold iden-
tified by investigators at the Mayo Clinic (i.e. 11.0¥109/L)8
was applicable to the patient series included in the
GIMEMA database. In this community-based patient
cohort, used as a test-set series, we clearly confirmed that
the threshold identified by Shanafelt et al.8 allowed
patients to be divided into two subsets with a higher and
a lower likelihood of treatment, respectively (HR 2.26;
95% CI 1.61-3.18; P<0.0001) (Figure 6).
Discussion
The diagnosis of asymptomatic chronic lymphocytic
leukemia has been based on the presence of an expanded
monoclonal B-cell clone and an increased absolute lym-
phocyte count. Although the immunophenotypic evalua-
tion of subjects with an absolute lymphocytosis is gener-
ally easy in the era of flow cytometry, there is no defini-
tive prospective or retrospective lymphocyte threshold
information which can help to establish a diagnosis of
chronic lymphocytic leukemia available.12 Our findings,
based on a large community-based cohort of patients who
underwent evaluation for an asymptomatic lymphocyto-
sis in different Italian hematological institutions referring
to the GIMEMA, basically confirm the observations of
Shanafelt et al.,8 thus suggesting that compared to absolute
lymphocyte count, the B-cell count better identifies those
patients who will require treatment from those with sta-
ble disease. This is in keeping with the recent
International Workshop on chronic lymphocytic leukemia
update of the National Cancer Institute 1996 guidelines
that modified the definition of chronic lymphocytic
leukemia, which now requires a B-cell count of 5.0¥109/L
cells, rather than the previous absolute lymphocyte count
of 5.0¥109/L.7
However, this proposed change has some shortcomings,
such as the absence of a standardized way to measure B-
cell counts. Flow cytometric immunophenotyping for
leukemia/lymphoma analysis is not a quantitative test and
no standardized approach for determining B-cell counts in
chronic lymphocytic leukemia has been proposed.13 On
the other hand, the method used for B-cell count measure-
ment in patients included in the GIMEMA multicenter
database is less accurate in comparison to the method uti-
lized in the Mayo Clinic studies.8,9 These technical differ-
ences reflect the absence of a centralized immunopheno-
typic standardization in the GIMEMA series and translate
B-cell count: differentiating chronic lymphocytic leukemia from monoclonal
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Figure 4. Time to first treatment (TFT) of patients stratified by ALC
greater than or less than 11.5¥109/L.
Figure 5. Time to first treatment (TFT) of patients stratified by B-cell
count greater than or less than 10.0¥109/L.
Figure 6. Time to first treatment (TFT) of patients stratified by B-cell
count according to Shanafelt et al.8 threshold (i.e. greater than or
less than 11.0¥109/L).
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into a slight variation in B-cell thresholds between the two
series. Furthermore, a shift from an absolute lymphocyte
count to a B-cell count could imply repeated flow cyto-
metric analyses to monitor the outcome of chronic lym-
phocytic leukemia. The relationship between B-cell count
and absolute lymphocyte count reported here (Figure 1A),
essentially in patients with a diagnosis of chronic lympho-
cytic leukemia, suggests that a reasonable practical
approach would be to monitor the patients with a B-cell
count above the diagnostic threshold (i.e. ≥5.0¥109/L B-
lymphocytes) and to reserve periodic B-cell assessments
by flow cytometry to patients with monoclonal B-cell
lymphocytosis until the chronic lymphocytic leukemia
diagnostic threshold is attained.
The diagnostic criteria for monoclonal B-cell lymphocy-
tosis were intended to identify individuals with an abnor-
mal B-cell population in the peripheral blood, but who did
not meet the current criteria for a B-cell lymphoprolifera-
tive disorder.6,8,9,14-16 In a recent study, Rawstron et al.6
reported the clinical outcome of a cohort of 185 CLL-type
monoclonal B-cell lymphocytosis cases observed over a
6.7-year period. The B-cell count (< or ≥1.9¥109/L) at the
time of the diagnosis of monoclonal B-cell lymphocytosis
was the only factor independently associated with pro-
gressive lymphocytosis; however, no association with
overall survival or time to first treatment was reported.
Shanafelt et al.9 described a lower likelihood of treatment
requirement for patients with a monoclonal B-cell lym-
phocytosis in comparison to patients with Rai stage 0
chronic lymphocytic leukemia. These findings could be
due, at least in part, to the lower median absolute B-cell
count at the time of diagnosis (2.7¥109/L vs. 3.9¥109/L) that
characterized the monoclonal B-cell lymphocytosis
patient cohort reported by Shanafelt et al.9 in comparison
to ours. Additionally, because the number of patients
reclassified as monoclonal B-cell lymphocytosis in the
GIMEMA database is lower in comparison to the MBL
patients of the Mayo Clinic series (15.1% vs. 40.1%), the
statistical power to detect the optimal diagnostic thresh-
old for monoclonal B-cell lymphocytosis/chronic lympho-
cytic leukemia is near the range of the current value of
5.0¥109/L. 
While the absolute lymphocyte count of 5.0¥109/L was
selected arbitrarily, there is the suggestion that the selec-
tion of an absolute B-lymphocytosis of 5.0¥109/L was like-
wise selected arbitrarily for consistency and was not based
on objective clinical data of outcome.12 As clearly illustrated
by monoclonal gammopathy of undeterminated signifi-
cance (MGUS), the distinction between a pre-neoplastic
and a neoplastic condition should rely on the individual
risk of an adverse clinical outcome rather than on the pres-
ence of a clonal cell population. In this respect, we confirm
that among patients with a clonal expansion of cells bear-
ing a CLL phenotype in the peripheral blood, the size of
the B-cell count relates to a patient’s risk of receiving ther-
apy for active disease. Our analysis clearly demonstrates
that the presence of a B-cell clone accounting for 10 ¥109/L
cells represents the best cut-off value to predict the clinical
behavior of the disease in terms of time to first treatment.
The same B-cell threshold, on the contrary, did not corre-
late with overall survival but the number of deaths record-
ed in the GIMEMA database was considered insufficient to
conduct an analysis of association between lymphocyte
parameters and overall survival. We would like to point out
that among the endpoints used to measure outcome, time
to first treatment appears more suitable than overall sur-
vival for early chronic lymphocytic leukemia patients.
Time to first treatment does not reflect competing risks
between successive relapses, histological transformations,
deaths in remission and the impact of new therapies.17
However, this does not mean that the association between
a B-cell lymphocyte threshold of 11.0¥109/L and overall
survival reported by the Mayo Clinic group does not hold.
In our retrospective community-based patient cohort,
the clinico-hematological characteristics, assessed at the
time of diagnosis, did not reflect changes in either the
absolute lymphocyte count or B-cell count. An unantici-
pated finding was represented by the statistically signifi-
cant difference in the median hemoglobin level between
groups. Indeed, there were more patients with mild ane-
mia (i.e. hemoglobin concentrations below the median
value for the whole series of 14 g/dL, but above 11 g/dL)
in the higher ALC/B-cell count group (51.9% vs. 40.6%;
P=0.001).
A limitation of our study is the lack of biologically-based
prognostic parameters, which were not always evaluated
at the time of diagnosis. This prevented us from perform-
ing a comprehensive multivariate analysis that included all
these variables. Although Shanafelt et al.8 demonstrated
that the B-cell count remained an independent predictor of
time to first treatment even after checking for ZAP-70,
CD38, IgVH or fluorescence in situ hybridization (FISH),
the prognostic independence of the size of the B-cell count
should be validated in an independent series of patients
monitored prospectively. On the contrary, one specific
strength of this report when compared to the studies of
Shanafelt et al.8,9 is represented by the characteristics of our
patient cohort which was taken from “primary” hematol-
ogy clinics; consequently, referral/ascertainment bias is not
an issue as it was in the Mayo Clinic studies.
In conclusion, our results, although based on a retro-
spective patient series, clearly justify retaining the B-cell
count as the reference gold standard of chronic lympho-
cytic leukemia diagnosis, but imply that a B-cell count of
10.0¥109/L represents the threshold that best predicts time
to first treatment. From a clinical standpoint, an interna-
tional and integrated clinical observational study including
patients with chronic lymphocytic leukemia in early stage
(from the time of first presentation) and followed prospec-
tively to better define disease outcome should conclusive-
ly address the issue. This is crucial to minimize the
unneeded psychological discomfort caused by labeling
individuals with laboratory abnormalities and/or low-risk
clinical features as having leukemia.18
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